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Abstract  
 
Premature ventricular contractions (PVCs) are common and 
are considered benign in the absence of structural heart disease. 
However, high burden of PVCs potentially on 24-hour Holter 
monitoring, can potentially cause left ventricular dysfunction. In 
this case, catheter ablation has been demonstrated to be effective 
at PVC suppression and is associated with improvement or 
normalization of ventricular function. This form of reversible 
ventricular dysfunction termed as PVC cardiomyopathy and its 
pathogenesis is poorly understood at the current time. Rhythmos 
2019;14(3):51-54.  
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Abbreviations: AIC = arrhythmia-induced cardiomyopathy; LV 
= left ventricular; LVEF = left ventricular ejection fraction; MRI 
= magnetic resonance imaging; PVC = premature ventricular 
contraction  
  
Introduction 
 
Premature ventricular contractions (PVCs) are 
common in daily clinical practice occurring either in 
patients with structural heart disease or in patients without 
heart disease. In the latter category of patients, PVCs can 
cause symptoms of palpitations and when they are frequent 
could cause reversible left ventricular (LV) dysfunction, 
characterized as a form of arrhythmia-induced 
cardiomyopathy (AIC). Idiopathic PVCs are commonly 
originated from the ventricular outflow tracts, either right 
or left. Less commonly, other foci such as epicardial tissue, 
papillary muscles or LV Purkinje system can produce 
PVCs.1-4 PVCs could be found in about 40% of 24-hour 
ambulatory electrocardiogram (ECG) recordings in the 
general population.5 Prevalence of PVCs increases with 
age and is estimated at > 69% in elderly subjects.5 The 
association between the presence of PVCs and mortality in 
patients with recent myocardial infarction was investigated 
in the Cardiac Arrhythmia Suppression Trial (CAST) I and 
II. The successful suppression of PVCs with encainide, 
moricizine and flecainide treatment was associated with 
increased mortality which was attributed to proarrhythmic 
effect of those antiarrhythmic agents.6,7 Later, several 
studies, reported a significant prevalence of PVCs in their 
populations. In the ARIC (Atherosclerosis Risk in 
Communities) study which enrolled over 14000 patients, 
6.1% of them had PVCs, and hypertension and obesity 
were identified as important predictors.8,9 Moreover, in this 
population a higher risk of heart failure and sudden cardiac 
death was reported in patients without known 
cardiovascular disease and frequent PVCs.10,11  
 
PVCs and Left Ventricular Dysfunction 
 
PVC-induced cardiomyopathy is classified as a form 
of AIC that includes cardiomyopathies induced by atrial or 
ventricular arrhythmias. The association of frequent PVCs 
with the development of AIC has been proposed in the 
literature several years ago. One of the first papers was 
published from Duffee et al in 1998 who described 
retrospectively the improvement of LV ejection fraction 
(LVEF) in a small population of patients with reduced 
(≤40%) LVEF and frequent PVCs (> 20,000/day) after 
treatment with amiodarone. 12 It remains unclear how 
exactly frequent PVCs produce LV dysfunction. 12 One of 
the proposed mechanisms is that PVC-induced 
cardiomyopathy is caused by a mechanism similar to 
tachycardia-induced cardiomyopathy as in other tachy-
arrhythmias, such as atrial fibrillation. However, patients 
with PVCs rarely develop sustained ventricular 
tachycardia episodes, since the most common form of 
tachycardia is the repetitive monomorphic ventricular 
tachycardia. Data from animal studies showed that after 
ventricular pacing in order to simulate high burden of 
PVCs, a form of cardiomyopathy was developed which 
was resolved 2-4 weeks after discontinuation of ventricular 
pacing without evidence of histopathological changes.13  
According to those data, some authors support the 
hypothesis that PVC-induced cardiomyopathy could be a 
result of ventricular dyssynchrony and ventricular 
remodeling, similar to that caused by left bundle branch 
block and chronic right ventricular apical pacing.14,15 
Animal studies have not detected cardiac fibrosis as a 
potential result of frequent PVCs.16 However, in patients 
with PVCs and preserved LV dysfunction, 
echocardiographic evaluation using speckle tracking has 
revealed slightly reduced left and right ventricular strain 
indicating a subtle ventricular dysfunction.17  
 
Predictors of PVC-Induced Cardiomyopathy and the 
Role of Catheter Ablation 
 
Epidemiological data have shown that not all patients 
with PVCs develop AIC. Risk factors have been identified 
as predictors of LV systolic dysfunction in these patients. 
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The most important risk factor seems to be the PVC burden 
which is defined as the percentage of PVCs on the 24h total 
number of beats. A PVC burden >20% has been associated 
with the development of heart failure.  More specifically, 
a PVC burden of 24% has been determined as a threshold 
associated independently with the development of PVC 
induced cardiomyopathy.18 Data derived from the 
population of the Cardiovascular Health Study (subjects 
with normal LVEF without heart failure symptoms who 
underwent 24-h Holter monitoring) showed that a PVC 
burden in the upper quartile (0.123–17.7%) was associated 
with three-fold greater odds of a decrease in LVEF, a 48% 
increased risk of heart failure, and a 31% increased risk of 
death, compared with the lower quartile.19 Moreover, the 
risk for the development of heart failure due to PVCs was 
8.1% (95% confidence interval: 1.2–14.9%), similar to 
other heart failure risk factors such as body mass index 
(BMI), hypertension, age, and coronary artery disease.19 
Moreover, male sex, multiform and asymptomatic PVCs 
are independent predictors of PVC-induced cardio-
myopathy. Epicardial origin as well as wider QRS duration 
of the PVCs are considered as markers of ventricular 
dyssynchrony which in turn leads to diastolic dysfunction 
and mitral regurgitation. The PVC coupling interval has 
also been studied, without being clear if it plays a role in 
LV dysfunction.20,21  
 
Catheter Ablation in Patients with PVC-Induced 
Cardiomyopathy  
 
Medical therapy with beta blockers or calcium 
channels blockers is considered as first line therapy in the 
management of PVC-induced cardiomyopathy. However, 
the success rate of PVC suppression varies among different 
patient categories. Beta blockers have been shown in a 
randomized trial to decrease PVC burden although they are 
limited by intolerance and variable effectiveness.22 
Moreover, amiodarone is generally the antiarrhythmic 
agent of choice in patients with LV dysfunction, however, 
it is limited by potential toxic effects. The use of Class IC 
antiarrhythmic agents in patients with cardiomyopathy is 
not recommended in common clinical practice due to high 
proarrhythmic risk according to the results of the CAST 
trial. Nevertheless, a recently published study which 
enrolled 20 patients with suspected PVC-induced 
cardiomyopathy who had undergone unsuccessful ablation 
procedures, reported that treatment with flecainide resulted 
in a decrease in the mean PVC burden from 36.2% to 
10.0%, and an increase in LVEF from 37.4% to 49.0%.23 
Catheter ablation of PVCs in patients with AIC has 
emerged as an important therapeutic strategy over the last 
several years especially in the setting of a single PVC 
morphology and origin from the outflow tract of either 
right or left ventricle. Comparing ablation to amiodarone, 
the percentages of successful suppression of PVCs are 
about 69% and 85% respectively. It should be noted that 
the discontinuation rate of amiodarone due to adverse 
effects was 27%.24 Data from many clinical studies, 
although the majority of them present retrospective 
analyses, have shown consistently favorable outcomes on 
LV function after elimination of PVCs with catheter 
ablation. Direct comparison of antiarrhythmic drugs versus 
ablation has been done only in a few clinical trials. Zhong 
et al. compared the efficacy of ablation and antiarrhythmic 
drugs in 510 patients with frequent PVCs (40% received 
drugs and 60% underwent ablation). Catheter ablation 
reduced significantly the PVCs, especially in patients with 
more than 10000 PVCs/24h. These patients experienced a 
greater improvement of LVEF after ablation compared to 
antiarrhythmic medication.21 Additionally, in 45 patients 
who underwent radiofrequency ablation for very frequent 
monomorphic PVCs, the elimination of the PVCs resulted 
in significant improvement in LVEF and reduction of end-
diastolic and end-systolic diameters of left ventricle after 
6-12 months of follow up.25 Patients who underwent 
ablation for PVCs due to LV dysfunction, the reduction of 
the PVC burden to 20% compared to baseline, resulted in 
recovery of LV systolic function in the majority of them 
(around 68%) in 4 months.26   
A similar study was published from Bogun et al who 
enrolled patients with frequent PVCs and idiopathic 
dilated cardiomyopathy. Successful ablation of PVCs led 
to improvement of LVEF. From the study population, 60 
patients with PVCs had no response to medical therapy. 
Twenty-two of these patients with high PVC burden and 
LVEF <50% underwent ablation, compared with the 
control group of 11 patients with similar PVC burden and 
LVEF who did not undergo ablation. LVEF improved 
from baseline of 34% to 59% ± 7% (P < 0.0001) within 6 
months in 18 patients who underwent ablation. The control 
group of 11 patients without ablation had no change in 
their LVEF over 19 months.26  
Complications from catheter ablation of PVCs are 
infrequent and were reported at 2.4% for major 
complications in a multicenter study. Most common were 
those which were related to vascular access and pericardial 
tamponade was reported in 0.8%. 28 Epicardial ablation via 
sub-xiphoidal puncture should only be performed by 
qualified operators additionally to endocardial or as first 
line approach when PVCs meet the criteria of epicardial 
origin. There are some PVC foci locations for catheter 
ablation such as LV summit, papillary muscles, and para-
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Hisian regions which are associated with lower success 
rates. 
As a successful ablation procedure is considered to be 
the elimination of PVCs accompanied by normalization or 
 10% improvement in LVEF. It is always challenging to 
predict in which patients with PVC-induced 
cardiomyopathy the LV function will improve following 
ablation. Although in these patients, the presence of late 
gadolinium enhancement on MRI is usually absent, its 
presence is considered to be a negative predictive factor 
for LVEF improvement.29 Other parameters such as the 
QRS width of the PVC and the duration of QRS during 
sinus rhythm can be used to assess the possibility of LVEF 
improvement. 30 Deyell et al. demonstrated that each 
increase in PVC-QRS duration of 10 ms is associated with 
an odds ratio of 5.07 (95% CI: 1.2 to 21.01) toward no 
recovery of the LVEF.31 This suggests that patients with 
wider PVC-QRS duration may have more severe 
underlying cardiac substrate abnormalities. 
 
Conclusion  
 
PVC-induced cardiomyopathy remains poorly 
understood as regards its pathophysiology and the reasons 
behind the fact that only some and not all patients show 
symptoms and signs of heart failure. At this time, catheter 
ablation is the only therapeutic approach that could 
improve the LVEF by reducing the burden of or 
eliminating PVCs. Compared to antiarrhythmic drugs, 
catheter ablation seems to be more effective without the 
complications of antiarrhythmic treatment. More data are 
needed in this field since existing clinical trials are not 
randomized and only few of them compare prospectively 
the two therapeutic strategies  
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